DCZ0415
DCZ0415 is a potent and selective TRIP13 inhibitor that demonstrates antimyeloma activity in vitro and in vivo, including in primary cells from drug-resistant patients. It functions by impairing non-homologous end joining repair and suppressing NF-κB signaling, making it a valuable tool for cancer research, particularly in studying myeloma pathogenesis and therapy resistance mechanisms.
Product Specifications
CAS Number
2242470-43-3
Product Name Alternative
Repair, TRIP13, end, DCZ 0415, DCZ0415, DCZ-0415, Inhibitor, myeloma, inhibit, joining, nonhomologous, NFkB, NF-kB, NFκB, NF-κB, Nuclear factor-κB, Nuclear factor-kappaB, drug-resistant, Apoptosis, anti-myeloma
Field of Research
Cell Biology, Signal Transduction
Purity
99.10% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.61 mM) ; DMSO:62.5 mg/mL (175.35 mM)
Smiles
O=C1C2C (C3C=CC2C2CC32) C (=O) N1c1ccc (Cc2ccncc2) cc1
Molecular Formula
C23H20N2O2
Molecular Weight
356.42
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
23781116 3x 1.0 µg
Homer1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
Sign In for Pricing
View Details